Persistent hypoxic pulmonary vasoconstriction (HPV) plays a significant role in the 20 pathogenesis of pulmonary hypertension (PH), which is an emerging clinical problem around the 21 world. We recently showed that hypoxia-induced activation of glucose-6-phosphate 22 dehydrogenase (Glc-6-PD) in pulmonary artery smooth muscle links metabolic changes within 23 smooth muscle cells to HPV, and that inhibition of Glc-6PD reduces acute HPV. Here we 24 demonstrate that exposing pulmonary arterial rings to hypoxia (20-30 torr) for 12 h in vitro, 25 significantly (P<0.05) reduces (by 30-50%) SM22α and smooth muscle myosin heavy chain 26 (SM-MHC) expression and evokes HPV. Glc-6-PD activity was also elevated in hypoxic 27 pulmonary arteries. Inhibition of Glc-6-PD activity prevented the hypoxia-induced reduction in 28 SM22α expression and inhibited HPV by 80-90% (P<0.05). Furthermore, Glc-6-PD and protein 29 kinase G (PKG) formed a complex in pulmonary artery, and Glc-6-PD inhibition increased PKG-30
INTRODUCTION
arteries exposed to hypoxia or normoxia ( Fig. 2B-F) , we observed no change in the expression 165 of β-actin and calponin, but SM22α and SM-MHC expression was significantly (P<0.05) reduced 166 under hypoxia. 167
Increased Glc-6-PD modulates persistent hypoxia-evoked pulmonary artery 168 contraction and changes in PASM cell phenotype -Because hypoxia-evoked increases in 169
Glc-6-PD levels contributes to acute HPV (15), we investigated the effect of prolonged hypoxia 170 on Glc-6-PD expression, and how this could alter HPV and the phenotype of PASM cells. 171
Exposing pulmonary arteries to hypoxia (12 h) significantly (P<0.05) increased Glc-6-PD 172 expression ( Fig. 3A) and activity (>1.5-fold), and this effect was attenuated by treating the 173 arteries with a competitive inhibitor, 6AN (1 mmol/L; Fig. 3B ). To verify the specificity of 6AN we 174 examined its effect on the Glc-6-PD activity in lungs from Glc-6-PD deficient mouse model. We 175 found 6AN reduced Glc-6-PD activity in lungs from wild-type (from 1.3 to 0.7 nmol/min/mg 176 protein) but not from Glc-6-PD deficient (from 0.7 to 0.5 nmol/min/mg protein) mice. This is 177 consistent with the earlier observation that 6AN induced relaxation of aortas from wild-type mice 178
but not Glc-6-PD deficient mice (3). To assess the effect of increased Glc-6-PD expression/activity 179 on HPV, we exposed endothelium-intact or -denuded pulmonary arteries to hypoxia or 180 normoxia, with or without 6AN. We found that prolonged HPV was significantly blunted by 6AN 181 in the presence and absence of endothelium ( Fig. 3C-D) , which suggests Glc-6-PD is involved 182 in mediating HPV. 183
To determine whether increases in Glc-6-PD activity could influence PASM cell contractile 184 phenotype protein expression, protein extracts from pulmonary arteries treated with 6AN under 185 hypoxia or normoxia were probed for contractile protein/phenotype markers by immunoblotting. 186 6-AN acts by competing with NADP + for the binding site on Glc-6-PD, which it irreversibly blocks 187 (16). Earlier studies, including ours, have shown that 6AN inhibits Glc-6-PD in many cell typesand in cancer cells, and thus retards cell proliferation and growth (47, 48) . For this reason, it is 189 used in cancer therapy as an anti-proliferative/neoplastic agent (16, 25) . 6AN treatment had no 190 significant effect on α-or β-actin expression under normoxia or hypoxia (Fig.3E-F ). Glc-6-PD 191 inhibition also did not significantly affect SM22α levels under normoxia, but it increased 192 (P<0.05) SM22α levels under hypoxia (Fig.3G) . Similarly, SM-MHC levels were unchanged by 193 6AN under normoxia, but were increased (P<0.05) under hypoxia (Fig.3H) 
arteries. 201
Inhibition of Glc-6-PD by 6AN activates PKG -Recent studies, including ours, have 202
shown that inhibition of Glc-6-PD using 6AN activates PKG in coronary and pulmonary arteries 203 (3, 40). We therefore examined whether 6AN-induced inhibition of Glc-6-PD activates PKG in 204 hypoxic pulmonary artery. 205
We first determined whether PKG regulates Glc-6-PD activity. Inhibition of PKG activity 206 using Rp-β-phenyl-1,N 2 -etheno-8-bromo-guanosine-3',5'-cyclic monophosphorothioate (RT-207 cGMPs), which inhibits PKG by binding to the cGMP binding site, reduced p-VASP in untreated 208
and KCl-treated pulmonary arteries. This suggests RT-cGMPs inhibited PKG in PASM. RT-209 cGMPs treatment did not alter Glc-6-PD activity (control: 2.0±0.5 and RT-cGMPs (100 nmol/): 210 hypoxia (Fig. 4A) . Inhibition of PKG did not alter hypoxia-induced increases in Glc-6-PD activity 213 in presence or absence of KCl (Fig. 4A) . However, KCl increased p-VASP-to-t-VASP ratios 214 under normoxia, while hypoxia reduced (P<0.05) p-VASP levels ( Fig. 4B-C) . RT-cGMPs 215 treatment further decreased p-VASP-to-t-VASP ratios, indicating PKG is inhibited under hypoxic 216 conditions ( Fig. 4B-C) . 217
Glc-6-PD-derived NADPH is an essential co-factor for many reductases in the cell, 218
including TxR, which reduce -S-S-bonds in proteins (39). Furthermore, Glc-6-PD deficiency or 219 inhibition is known to decrease TxR activity in several mammalian cell types (2). We therefore 220 speculated inhibition of Glc-6-PD activity (under conditions that decrease NADPH) may 221 attenuate TxR activity. Decreased TxR activity could then oxidize cysteine residues in PKG (31), 222 and activate it. If this presumption is correct then these three proteins should be in close 223 proximity in the cell. Therefore, we performed immunoprecipitation of PKG and TxR-1 from PA 224 homogenates with anti-PKG and -TxR-1 antibody and Western blotting with anti-Glc-6-PD and -225 PKG antibody. Figure 4D -E, demonstrates TxR-1, Glc-6-PD and PKG appears to form a 226 complex in PAs. Intriguingly, Glc-6-PD inhibition by 6AN in the presence of KCl markedly 227 increased p-VASP-to-t-VASP ratios, demonstrating that inhibition of Glc-6-PD activated PKG 228 (Fig. 4F-G) . This led us to implicate increase in Glc-6-PD activity inactivates the PKG activity by 229 either up-regulating NADPH under hypoxia, and conversely inhibition of Glc-6-PD using 6AN 230 increases PKG activity. 231
Inhibition of Glc-6-PD by 6AN activates PKG and inhibits hypoxia-evoked decrease 232 of SM22α and pulmonary artery contraction -To assess the role of activated Glc-6-PD in 233 hypoxia-induced contraction and phenotypic modulation of PASM; we determined the effect ofdehydroepiandrosterone, an uncompetitive Glc-6-PD inhibitor, and 6AN also increased 241 myocardin, but not SM22α expression in PKG-deficient pulmonary artery smooth muscle cells 242 cultured in hypoxia for 72 hrs (Fig. 5B) . We also found that PKG inhibition reduced levels of 243 SM22α and SM-MHC in hypoxic pulmonary arteries, and that RT-cGMPs inhibited 6AN-evoked 244 increases in SM22α/SM-MHC/calponin levels, without affecting levels of actin (Fig. 5C) . 245
Interestingly, PKG inhibition also diminished the 6AN-induced inhibition of hypoxia-induced 246 pulmonary artery contraction (Fig. 5D ), without affecting KCl (30 mmol/L)-evoked contraction 247 (Control: 94.8±5.4% vs RT-cGMPs: 98.4±7.2% of 120 mmol/L KCl). 248
Stretch stimulates Glc-6-PD and PKG-dependent phenotypic modulation in 249 pulmonary arteries exposed to hypoxia -Pulmonary arteries are highly compliant, but the 250 increases in pulmonary artery pressure seen under hypoxia puts a high degree of stress on the 251 vessel walls (44). We therefore studied the effect of increasing passive tension on the 252 pulmonary artery wall on expression of Glc-6-PD and PASM phenotypic markers. Pulmonary 253 arterial levels of calponin and β-actin were unaffected by increasing passive tension (from 0.8 g 254 to 3 g) in hypoxia or normoxia (representative arteries from 3 different animals were pooled 255 together to obtain sufficient protein for immunoblotting). But surprisingly we found that levels of 256
Glc-6-PD decreased, while both p-VASP and SM22α increased with increases in passive 257 tension under hypoxia (Fig. 6A ). When KCl-induced contractions were elicited in arteries at 258 different levels of passive tension, we found that chronic hypoxia (12 h) increased the force of 259 contraction at low (0.8 g) passive tension, but led to relaxation upon application of higher (3.0 g) 260 passive tension (Fig. 6B ). We speculated that the relaxation seen under hypoxia with highertension could partly be due to up-regulation of PKG activity under hypoxia, which may lead to 262 less α-actin-myosin cross-bridge cycling and loss of contractile force. In order to assess α-actin-263 myosin interactions, we immunostained frozen sections of pulmonary arterial rings subjected to 264 0.8 g or 3.0 g of tension under normoxia and hypoxia. We observed increases in the interaction 265 (orange to yellow) of actin (green) with SM-MHC and SM-pMLC (both red) under chronic 266 hypoxia at 0.8 g tension. With 3.0 g of tension, by contrast, we saw no increase in the α-actin-267 SM-MHC or α-actin-SM-pMLC interaction (Fig. 6C) . Furthermore, co-immunoprecipitation of α-268 actin and SM-MHC (Fig. 6D) confirms the immunofluoresence findings. 269
In the present study, we have shown that exposing the pulmonary artery to hypoxia 272 increases active contraction, decreases expression of the contractile proteins, and SM22α and 273 SM-MHC. Interestingly, Glc-6-PD inhibition led to activation of PKG, which in turn inhibited the 274 hypoxia-induced phenotypic modulation in PASM cells and attenuated hypoxia-induced 275 contraction of PAs. 276
Cells and organisms are able to very quickly adapt biochemically and physiologically to 277 changes in pO 2 tension (21). It has been known for more than 100 years that systemic arteries 278 dilate and pulmonary arteries constrict in response to hypoxia, and numerous studies have been 279 conducted to decipher the molecular mechanisms involved in this adaptation (1, 21, 29) . 280
Although identity of the pO 2 sensor is somewhat known, still the effectors that mediate hypoxic 281 responses within blood vessels remains unknown. The pO 2 sensor rapidly detects changes in 282 pO 2 , and vascular smooth muscle quickly (within minutes) responds by either contracting or 283
relaxing (21). 284
Pulmonary arteries contract in response to hypoxia to divert blood away from poorly 285 ventilated areas toward well-ventilated areas of the lungs. In addition, hypoxia stimulates the 286 synthesis and release of endothelium-derived factors (endothelin, prostanoids, thromboxanes 287 and serotonin) that all contribute to the hypoxic contraction (29, 49). Our results suggest that 288 endothelium influences the contractility of pulmonary arteries in the early phase of the HPV 289
response. 290
A number of theories have been put forth to explain how hypoxia increases active force: 291 inhibition of K v1.5 channel function and expression, activation of Ca 2+ channels (L-type Ca 2+ and 292 store-operated Ca 2+ channels), potentiation of Ca 2+ release from internal stores, and increased 293 sensitivity of the myofilaments to Ca 2+ are all thought to contribute to HPV (29, 49) . Our earlierstudies showed that Glc-6-PD mediates acute HPV and that hypoxia does not evoke contraction 295 in pulmonary arteries isolated from Glc-6-PD deficient mice. Concurrently, other studies showed 296 that Glc-6-PD inhibitors reduce PH (5, 15, 19, 20, 24, 42) . We now found that stimulation of 297 PKG (measured as VASP phosphorylation) through Glc-6-PD inhibition reduces hypoxia-298 induced pulmonary artery contraction, and this inhibition is partially reversed by RT-cGMPs, a 299 PKG inhibitor. Our results also suggest that TxR-1, Glc-6PD and PKG form a complex. We 300 therefore propose that PKG activation, presumably via redox changes (3, 40), secondary to Glc-301 6-PD and TxR-1 inhibition is another novel pathway via which Glc-6-PD inhibitors reduce HPV. 302
We also found that hypoxia induces a reduction in pulmonary arterial expression of 303 SM22α and SM-MHC expression, without affecting actin expression. Consistent with those 304 results, hypoxia is known to reduce the promoter activity of multiple smooth muscle cell marker 305 genes in ovine fetal pulmonary venous smooth muscle cells and in primary PASM cells (26, 52) , 306
and to facilitate trans-differentiation of endothelial and progenitor cells into PASM cells (27, 53) . 307
It has been suggested that down regulation of SM22α and tropomyosin expression reduces 308 hypoxia-induced relaxation of porcine coronary arteries (46), but the physiological function of 309 SM22α in smooth muscle is only poorly understood (23, 37). For example, it remains 310 controversial whether SM22α binds to actin (12, 37). Some studies suggest active force is 311 reduced in mesenteric resistance arteries and portal veins from SM22α -/-mice (51), while others 312 have proposed that SM22α inhibits actin-myosin interaction (46). Moreover, generally changes 313 in SM22α expression are associated with the phenotypic modulation of PASM (37, 43) . 314
Likewise, reduced expression of SM-MHC is also thought to reflect phenotypic modulation of 315 smooth muscle (10). Consistent with that notion we also found that cell cycle/pro-proliferative 316 proteins (PCNA and Ki-67) slightly increased in hypoxic PASM. Our results thus suggest 317 hypoxia induces arterial contraction along with biochemical changes that foster PASM 318 proliferation and contribute to the remodeling of the pulmonary artery to protect against thehigher (from 20 to 100 mmHg) arterial pressures. However, the smooth muscle proliferation 320 further increases pressure by reducing luminal cross-sectional area and ultimately obliterate 321 arterial branches in PH. 322
Changes in the expression of contractile proteins induced by persistent hypoxia were 323 also prevented by 6AN, which acts by competitively inhibiting Glc-6-PD (16). Interestingly, 324 treating pulmonary artery with 6AN for 12 h increased expression of SM22α and SM-MHC. This 325 suggests that 6AN prevented or reduced HPV by simultaneously reducing Ca 2+ -mediated active 326 force development (15), and inhibiting the phenotypic modulation of smooth muscle cells (Fig 3) . 327
This response appears to be mediated via the PKG pathway, as the effects of 6AN, including 328 increased phosphorylation of VASP was inhibited by RT-cGMPs. These results clearly 329 demonstrate that hypoxia induces activation of Glc-6-PD and reduces levels of p-VASP, and 330 that hypoxia-induced modulation of PASM cell phenotype was mediated by Glc-6-PD via the 331
PKG pathway. 332
PKG is well known to control vascular smooth muscle phenotype, in part by stimulating 333 myocardin/serum response factor (SRF)-dependent gene expression (8, 33). Inhibition of PKG 334 in ovine fetal pulmonary venous smooth muscle cells down regulates the expression of 335 myocardin, but up regulates expression of Elk-1 (52). Alternatively, PKG may reduce Elk-1 336 activity through sumo modification, thereby increasing myocardin-SRF-dependent smooth 337
muscle-specific gene expression in vascular smooth muscle cells (8). Because down regulation 338
(by 52.14%) of myocardin expression in hypoxic pulmonary arteries was prevented by 6AN via a 339 PKG-independent pathway, we suggest that activation of PKG by 6AN reduces Elk-1-induced 340 inhibition of SRF-sensitive smooth muscle-specific genes, like SM22α. 341
Expression of PKG in PKG-deficient vascular smooth muscle cell line results in an 342
increased production of contractile phenotype marker proteins such as; SM-MHC, calponin andregulating the expression of these contractile proteins in pulmonary artery smooth muscle cells 345
co-cultured with endothelial cells (13).
It is, therefore, reasonable to speculate that 346 endothelium-derived signals may influence the expression of SM-MHC and SM22α proteins in 347 intact pulmonary artery as well. Since hypoxia diminished PKG activity in pulmonary artery, we 348 speculate that this might have resulted in decreasing SM22α and SM-MHC expression in 349 pulmonary artery. Moreover, as illustrated in a schematic (Fig. 7) our results provide novel 350 evidence for additional Glc-6-PD-dependent redox-and O 2 tension-sensitive mechanisms that 351 inactivate PKG and control the expression of these contractile proteins in smooth muscle. 352
The tensile stress added to the vascular wall by increasing pressure is a 353 physical/mechanical factor that stimulates pulmonary arterial remodeling in PH (34). Increases 354 in pulmonary arterial pressure have been shown to depolarize PASM cell membranes in 355 pulmonary hypertensive rats (6, 50). Wall stress-induced deformation of elastic laminae and 356 thickening of extra-cellular matrix is also thought to evoke pulmonary artery remodeling in 357 chronic hypoxia-induced PH (30, 34). Moreover, static stretch is known to promote DNA 358 synthesis in cultured rat pulmonary arteries (50) and to increase KCl-induced active contraction 359 of bovine pulmonary arteries (41), but reduce active circumferential tension and stress in 360 vessels from monocrotaline-treated rats (32). Although physical stress had no obvious effect on 361 the expression of vascular smooth muscle phenotype markers under normoxia, their expression 362 was altered by increases in passive tension in hypoxic pulmonary arteries. Intriguingly, Glc-6-363 PD expression declined linearly with increasing passive tension under hypoxia, and expression 364 of both p-VASP and SM22α was increased. We also observed that arteries resting at 3.0 g 365 passive tension relaxed instead of contracting in response to hypoxic stimuli. We suggest that a 366 reduction in actin-myosin interaction evoked by the increase in PKG activity could bein COPD (bronchitis, emphysema, asthma and lung cancer) patients and individuals living at 373 high altitude (45). In idiopathic or familial primary pulmonary arterial hypertension, 374 constriction/obliteration of the pulmonary arteries causes generalized hypoxia (38, 45) . 375
However, the molecular mechanism(s) by which hypoxia evokes pulmonary artery constriction 376 and remodeling during the pathogenesis of PH is still not well understood (11). We found that 377 hypoxia stimulates Glc-6-PD, which increases pulmonary artery contraction, and speculated that 378 activated Glc-6-PD contributes to persistent HPV and PH. The present findings indicate that 379 increases in Glc-6-PD activity influence contraction, PKG activity and PASM cell phenotype, all 380 of which affect pulmonary artery remodeling. We believe that a fuller understanding of how 381
Glc-6-PD regulates pulmonary arterial phenotype and vasomotor tone could lead to the 382 development of new strategies to reverse PH. 383
In summary, we propose that within PASM cells Glc-6-PD serves as a link between the 384 pO 2 sensor and the effectors that mediate HPV. If so, Glc-6-PD could be an important new 385 therapeutic target. Indeed, our findings suggest that inhibition of Glc-6-PD could simultaneously 386 diminish activity in several pathways that promote PH. 387 HL43023 and HL66331) and TML (HL053426 and HL066164) . 
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Ward contractions is shown. (B) Once the isometric force reached a steady state, the arteries were 557 exposed to hypoxia (95% N 2 , 5% CO 2 ; n=5) or normoxia (21% O 2 , 5% CO 2 ; n=5) for 12 h. A 558 typical tracing of pulmonary artery exposed to hypoxia. (C) Summary data showing the effect of 559 hypoxia on endothelium-denuded and intact pulmonary arteries. Although endothelium-denuded 560 arteries acutely contracted with hypoxia, there was no difference in maximum active force 561 developed between endothelium-intact and denuded pulmonary arteries after prolonged 562 hypoxia. 563 PD expression was increased in bovine pulmonary arteries exposed to prolonged hypoxia 575 (n=4). (B) 6AN (1 mmol/L; 12 h; n=5), a potent inhibitor of Glc-6-PD, significantly inhibited Glc-6pulmonary arteries. (E-F) Inhibition of Glc-6-PD using 6AN had no effect on α-and β-actin 579 expression in pulmonary arteries exposed to hypoxia or normoxia for 12 h. With Glc-6-PD 580 inhibition under hypoxia, SM22α expression increased (G), while SM-MHC expression 581 increased (H). Normoxic and hypoxic samples were run on one gel in blinded fashion; after the 582 blot was developed, lanes containing samples irrelevant to this figure were removed from the 583 picture. 584 TxR-1, -Glc-6-PD and -PKG antibodies demonstrate that these 3 proteins co-exist in a complex 593 in pulmonary artery smooth muscle. Note input lanes containing samples irrelevant to this figure  594 were removed from the picture and exposure time for self IP blots were significantly lesser than 595 cross IP blots to avoid masking of TxR band in IgG heavy chain. (F-G) Inhibition of Glc-6-PD 596 using 6AN (1 mmol/L) markedly increased PKG activity (n=5) in the presence of KCl (30 597 mmol/L). 598 Schematic illustrating of a potential pathway through which hypoxia affects activity of Glc-6-PD 627 and PKG, and expression of contractile proteins. Inhibition of Glc-6-PD-derived NADPH redox 628 reduces thioredoxin reductase-1 (TxR-1) activity, which oxidizes thiols on PKG and activates it. 629
Increase in PKG activity re-expresses contractile proteins, while myocardin expression is 630 increased in PKG-independent manner. 
